.

Alnylam Pharmaceuticals reported $184.01M in Gross Profit on Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 131.9M 19.38M
Agios Pharmaceuticals AGIO:US $ 5.15M 4.65M
Alnylam Pharmaceuticals ALNY:US $ 184.01M 6.38M
Amgen AMGN:US $ 5084M 407M
Biocryst Pharmaceuticals BCRX:US $ 65.28M 15.6M
Biomarin Pharmaceutical BMRN:US $ 410.67M 8.28M
Bluebird Bio BLUE:US $ -226000 6.14M
Intercept Pharmaceuticals ICPT:US $ 71.45M 16.38M
IONIS PHARMACEUT IONS:US $ 129.05M 8.7M
Moderna Inc MRNA:US 3.37B 1.68B
Neurocrine Biosciences NBIX:US $ 373.4M 67.4M
Novartis NVS:US $ 9336M 277M
Ptc Therapeutics PTCT:US $ 155.89M 17.29M
Regeneron Pharmaceuticals REGN:US $ 2560.1M 0.1M
Sarepta Therapeutics SRPT:US $ 195.69M 16.3M
Takeda 4502:JP Y 679583M 114674M
Ultragenyx Pharmaceutical RARE:US $ 81.07M 7.24M
Vertex Pharmaceuticals VRTX:US $ 1934.4M 82.7M
YTE INCY:US $ 866.16M 170.14M